Erbitux

Cetuximab

Epidermal growth factor receptor (EGFR) expressing RAS wild-type metastatic CRC (mCRC) in combination w/ irinotecan-based chemotherapy, 1st-line combination w/ FOLFOX, as single agent after failure of oxaliplatin- & irinotecan-based therapy & for patients' intolerant to irinotecan. Squamous cell head & neck cancer in combination w/ radiation therapy for locally advanced disease & in combination w/ platinum-based chemotherapy for recurrent &/or metastatic disease.

1-hr prior to 1st infusion, patient must receive premed w/ antihistamine & corticosteroid. Initially 400 mg/m² once wkly. Max infusion rate: 5 mg/min for 120 min. Subsequent wkly dose: 250 mg/m² once wkly. Max infusion rate: 10 mg/min for 60 min. IV administered w/ infusion pump, gravity dip or syringe pump.

Hypersensitivity. Combination w/ oxaliplatin-containing chemotherapy in patients w/ mutant RAS mCRC or unknown RAS mCRC status. Concomitant use of chemotherapeutic agents or radiation therapy.

Severe infusion-related reactions including anaphylactic reactions; history of allergy to red meat or tick bites or +ve IgE Ab test results. Discontinue use if ILD is diagnosed. Temporary interruption if severe skin reactions occur. Not be used for CRC patients whose tumours have RAS mutations or unknown status. Patients w/ reduced performance status, preexisting cardiopulmonary diseases & haematological disorders; neutropenia & related infectious complications; CV status; history of keratitis, ulcerative keratitis or severe dry eye. Patients w/ confounding or contributing factors eg, concomitant chemotherapy associated w/ ILD & preexisting pulmonary diseases. Determine serum electrolyte levels prior to & periodically thereafter. Concomitant use w/ cardiotoxic compd eg, fluoropyrimidines; combination w/ radiation therapy in CRC. Contact lens users. May affect ability to drive & use machines. Hepatic & renal impairment. Pregnancy. Not recommended during lactation. Childn <18 yr. Elderly ≥75 yr.

Skin reactions; hypomagnesaemia; increased liver enzyme levels; mild or moderate infusion-related reactions, mucositis. Dehydration, hypocalcaemia, anorexia; headache; conjunctivitis; diarrhoea, nausea, vomiting; severe infusion-related reactions, fatigue.

Increased frequency of severe leukopenia or neutropenia w/ platinum-based chemotherapy. Increased frequency of cardiac ischaemia w/ fluoropyrimidines. Increased frequency of severe diarrhoea w/ capecitabine & oxaliplatin.

Targeted Cancer Therapy

L01FE01 - cetuximab ; Belongs to the class of EGFR (Epidermal Growth Factor Receptor) inhibitors. Used in the treatment of cancer.

B